美国酝酿出台新一轮财政刺激措施,美股涨跌不一 , 标普指数三连涨

资讯摘要

美股周二收盘涨跌不一,科技股拖累纳指走低。标普500指数录得连续第三个交易日上涨。美国国会正就新一轮财政刺激方案进行谈判。欧盟达成突破性的财政刺激协议。
 
  • 美股资讯
北京时间7月22日凌晨,美股周二收盘涨跌不一,科技股拖累纳指走低。标普500指数录得连续第三个交易日上涨。美国国会正就新一轮财政刺激方案进行谈判。欧盟达成突破性的财政刺激协议。道指涨159.53点,或0.60%,报26840.40点;纳指跌86.73点,或0.81%,报10680.36点;标普500指数涨5.46点,或0.17%,报3257.30点。周二开盘纳指最高上涨至10839.93点,创盘中历史新高。但随着Facebook、亚马逊、Netflix、微软及苹果等大型科技股走低,纳指回吐涨幅并最终收跌。原油与银行板块普涨,道指成分股雪佛龙公司收高7.2%,埃克森美孚公司上涨5.1%,美国运通涨2.5%,摩根大通涨2.2%。
 美国酝酿出台新一轮财政刺激措施 市场参与者也在关注美国的新一轮财政刺激计划进展。美国现行的规模超过2万亿美元的《冠状病毒援助、救济和经济安全法案》将于本月底到期。美国财政部长史蒂文-姆努钦表示,总值达万亿美元的刺激计划正在开始制定。美国国会从周二至周五将继续讨论新一轮财政刺激方案。姆努钦和众议院议长南希-佩洛西将于周二下午开始与其他议员一起开始讨论。

 

冠状病毒疫苗研发进展

据约翰斯-霍普金斯大学疫情统计数据显示,截至北京时间7月21日20:00,美国累计确诊病例383.14万例,累计死亡14.09万例。医学杂志《柳叶刀》7月20日发布的最新数据显示,英国牛津大学与阿斯利康公司合作研发的一种可能的冠状病毒疫苗在大规模的早期人体试验中产生了良好的免疫反应。 
 

在新冠疫情形势形势仍然严峻之际,市场对于疫苗的期望似乎更为强烈。因此,一旦出现疫苗的利好消息,都会极大地提振市场风险情绪,进而刺激股市、商品等资产走势。

周二,来自默沙东集团、Moderna 、辉瑞制药、阿斯利康和强生等公司的高管将在美国国会众议院能源与商业委员会发表证词,以阐述其在冠状疫苗接种研究方面的工作。
 
 
焦点个股:
 
IBM第二季度业绩超市场预期。该公司二季度实现营收181.2亿美元,同比下降5.4%,但高于分析师预计的177.2亿美元;净利润为13.6亿美元,同比下降46%。可口可乐二季度净利润为17.79亿美元,市场预期23.1亿美元,去年同期为26.07亿美元。特斯拉上海超级工厂Model Y冲压设备安装已基本完成。另据报道,该公司计划在三季度实现创纪录的交付量。二季度,该公司交付量同比仅下降了5%,而其他大多数汽车制造商的交付量下降了30%或更多。
 
热点中概股

 

  • 香港资讯

北京时间7月21日,美股周一收高,科技股领涨。纳指创收盘历史新高。投资者关注疫情及疫苗研发进展、企业财报、美国国会关于新一轮财政刺激的谈判等。今日开盘,恒指高开1.47%,午后涨幅扩大至2%。

截止收盘,恒生指数涨2.31%,报25635.66点,国企指数涨1.46%,红筹指数涨0.93%。

 

热点板块:

内地医药股上涨。平安好医生涨9.62%,中国生物制药涨6.96%,复星医药涨6.62%。

科技股集体走高,腾讯涨7.94%,美团涨8.81%,小米涨4.93%,京东涨5.13%,网易涨5.52%。恒生指数公司将于2020年7月27日推出恒生科技指数。新指数将会追踪经筛选后最大30间于香港上市的科技企业。经筛选后,市值最大的30只股票将被纳入成为指数成份股,其中包括阿里巴巴、美团点评、腾讯控股、小米集团。受益于此,港交所暴涨9.83%。

阿里巴巴股价大涨7.26%,报251.8港元。阿里系也集体上涨,中国动向涨31.76%,阿里健康涨13.82%,云锋金融涨6.8%。阿里巴巴旗下蚂蚁金服官宣启动在上交所科创板和港交所主板寻求同步发行上市的计划。市场消息显示,蚂蚁金服本次上市,估值至少2000亿美元。根据阿里巴巴年报,阿里巴巴持股蚂蚁金服33%的股权,君瀚和君澳持有蚂蚁金服50%股权,而君瀚属于马云及阿里系、蚂蚁系员工,君澳属于阿里巴巴合伙的部分成员。因此,阿里巴巴及阿里系成员大约持股蚂蚁金服大约83%的股权,目前马云持股蚂蚁金服8.8%,拥有50%表决权。 

 

全天涨幅最大的5支港股通

  • 中国资讯

 

北京时间7月21日,三大指数早盘高开高走,创业板指拉升涨逾1%,深成指、沪指也继续上攻。盘面上,受消息刺激,蚂蚁金服概念上演涨停潮,数字货币概念也拉升走强。前期回调猛烈的白酒股迎来反弹。总体上,早盘市场人气较为活跃,资金做多情绪高涨。临近上午收盘,沪指一度回落翻绿,创业板跌幅收窄,随后指数稍有回升。盘面上,两市逾2600只个股下跌。蚂蚁金服概念涨幅持续回落,多股炸板。多空争夺较为激烈,赚钱效应较差。午后,指数延续震荡态势。盘面上,疫苗板块全线大涨,个股跌多涨少,赚钱效应较差。尾盘,指数震荡走高,沪指翻红向上,创指大涨1.7%。盘面上,互联网医疗与疫苗板块午后大涨,NMN板块再度活跃,板块个股涨跌参半。两市成交额也再度突破万亿,已连续十四个交易日突破万亿。

截至收盘,沪指报3320.89点,涨0.20%,成交额为5440亿元;深成指报13536.17点,涨0.65%,成交额为6142亿元;

截至收盘,蚂蚁金服、NMN、白酒居板块涨幅榜前列,军工、环保工程、券商居板块跌幅榜前列。

 

热点板块:

 
蚂蚁金服概念股汇鸿集团、海泰发展、张江高科、朗新科技、高伟达、新开普、易联众等多股走强。

消息面上蚂蚁集团宣布,计划在上交所科创板和港交所主板寻求同步发行上市,进一步支持服务业数字化升级做大内需,支持公司加大技术研发和创新。蚂蚁集团是支付宝的母公司,致力于以科技推动包括金融服务业在内的全球现代服务业的数字化升级。

白酒板块拉升,古井贡酒、山西汾酒、金种子酒、贵州茅台、酒鬼酒、五粮液等多股跟涨。

消息面上上周受媒体对茅台评论文章事件影响,引发市场猜测,市场情绪波动带来板块急跌。华创证券指出,从事件本身看,近期茅台批价和股价均大幅上涨,受到舆论关注,评论文章内容主要针对近期黄牛倒货热,而非茅台品牌本身。结合近期贵州省内已加大对黄牛的打压,实际上已在压制价格投机风气,防止酒价过热风险,呵护茅台品牌行稳致远。

 
全天涨幅最大的5支沪深股通

信息数据来源:东方财富网、同花顺、新浪财经、腾讯证券、华尔街见闻、辉立证券

 

声明:本文仅为提供咨询,并不构成提议或者诱使预定、购买或销售在此提及的投资商品。它与您的任何投资目的、财务状况或者您的任何特定需求无关。因此,我们将不提供任何允诺也不为您因为该资讯所进行交易但导致的直接或间接的损失而负责任。所有投资都包含一定的投资风险,包括失去投资本金的可能性。您的账户和获得的服务可能受到市场状况、系统性能和其他因素的影响。第三方的研究信息来源可靠,尽管如此,辉立证券私人有限公司不保证它准确性和完整度,也不对因使用此讯息而导致的结果进行担保。 在决定进行交易之前,您可征询财务顾问的专业意见。如果您决定不寻求财务顾问的意见,您应该考虑此产品是否适合您。我们建议您在通过辉立市进行交易之前仔细阅读并理解辉立证券交易账户管理条件和风险披露声明。
 

如果有想了解更多全球股市资讯,请关注微信公众号 “辉立资本新加坡” (SGPSPL)。同时提供在线免费开设股票账户,一个账户轻松交易全球股票和ETF

美股,港股,新加坡股,中国A股,越南股票,韩国股票,德国股票,马来西亚股票,泰国股票,印尼股票,菲律宾股票,日本股票,澳大利亚股票,台湾股票,加拿大股票,英国股票,法国股票,荷兰股票,葡萄牙股票,比利时股票,土耳其股票

如果本文是英文翻译版本,一切请以英文为准

联系我们开设账户

需要帮助吗?请分享您的详细资料,我们会给您答复。

IMPORTANT INFORMATION

This material is provided by Phillip Capital Management (S) Ltd (“PCM”) for general information only and does not constitute a recommendation, an offer to sell, or a solicitation of any offer to invest in any of the exchange-traded fund (“ETF”) or the unit trust (“Products”) mentioned herein. It does not have any regard to your specific investment objectives, financial situation and any of your particular needs. You should read the Prospectus and the accompanying Product Highlights Sheet (“PHS”) for key features, key risks and other important information of the Products and obtain advice from a financial adviser (“FA“) pursuant to a separate engagement before making a commitment to invest in the Products. In the event that you choose not to obtain advice from a FA, you should assess whether the Products are suitable for you before proceeding to invest. A copy of the Prospectus and PHS are available from PCM, any of its Participating Dealers (“PDs“) for the ETF, or any of its authorised distributors for the unit trust managed by PCM.  

An ETF is not like a typical unit trust as the units of the ETF (the “Units“) are to be listed and traded like any share on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Listing on the SGX-ST does not guarantee a liquid market for the Units which may be traded at prices above or below its NAV or may be suspended or delisted. Investors may buy or sell the Units on SGX-ST when it is listed. Investors cannot create or redeem Units directly with PCM and have no rights to request PCM to redeem or purchase their Units. Creation and redemption of Units are through PDs if investors are clients of the PDs, who have no obligation to agree to create or redeem Units on behalf of any investor and may impose terms and conditions in connection with such creation or redemption orders. Please refer to the Prospectus of the ETF for more details.  

Investments are subject to investment risks including the possible loss of the principal amount invested. The purchase of a unit in a fund is not the same as placing your money on deposit with a bank or deposit-taking company. There is no guarantee as to the amount of capital invested or return received. The value of the units and the income accruing to the units may fall or rise. Past performance is not necessarily indicative of the future or likely performance of the Products. There can be no assurance that investment objectives will be achieved.  

Where applicable, fund(s) may invest in financial derivatives and/or participate in securities lending and repurchase transactions for the purpose of hedging and/or efficient portfolio management, subject to the relevant regulatory requirements. PCM reserves the discretion to determine if currency exposure should be hedged actively, passively or not at all, in the best interest of the Products.  

The regular dividend distributions, out of either income and/or capital, are not guaranteed and subject to PCM’s discretion. Past payout yields and payments do not represent future payout yields and payments. Such dividend distributions will reduce the available capital for reinvestment and may result in an immediate decrease in the net asset value (“NAV”) of the Products. Please refer to <www.phillipfunds.com> for more information in relation to the dividend distributions.  

The information provided herein may be obtained or compiled from public and/or third party sources that PCM has no reason to believe are unreliable. Any opinion or view herein is an expression of belief of the individual author or the indicated source (as applicable) only. PCM makes no representation or warranty that such information is accurate, complete, verified or should be relied upon as such. The information does not constitute, and should not be used as a substitute for tax, legal or investment advice.  

The information herein are not for any person in any jurisdiction or country where such distribution or availability for use would contravene any applicable law or regulation or would subject PCM to any registration or licensing requirement in such jurisdiction or country. The Products is not offered to U.S. Persons. PhillipCapital Group of Companies, including PCM, their affiliates and/or their officers, directors and/or employees may own or have positions in the Products. Any member of the PhillipCapital Group of Companies may have acted upon or used the information, analyses and opinions herein before they have been published. 

This advertisement has not been reviewed by the Monetary Authority of Singapore.  

 

Phillip Capital Management (S) Ltd (Co. Reg. No. 199905233W)  
250 North Bridge Road #06-00, Raffles City Tower ,Singapore 179101 
Tel: (65) 6230 8133 Fax: (65) 65383066 www.phillipfunds.com